Unfolding the role of protein misfolding in neurodegenerative diseases
The DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neurodegenerative diseases, such as AD and DLB, are often characterized as diseases of protein aggregation (30–33).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [30]
In the citing paper
“Importantly, most of these age-related primary neurodegenerative diseases involve disorders of protein processing and aggregation.”
From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [59]
In the citing paper
“The hallmark feature of these proteinopathies are the fibrillary aggregates of misfolded or hyperphosphorylated proteins (59).”
From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [59]
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundMACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
Background
Cited by
Items 401–500 of 1,001
Astrocytes and endoplasmic reticulum stress: A bridge between obesity and neurodegenerative diseases
Martín-Jiménez, C., García-Vega, Á. S., Cabezas, R., Aliev, G., Echeverría, V., González, J., & Barreto, G. E. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.001 · Cited by 57
“body of evidence indicates that both PERK pathway and CHOP activation are involved in neurodegeneration (Table 2) (Chaudhari et al., 2014; Doyle et al., 2011; D. Lindholm et al., 2006; T. Ma & Klann, 2014; Malhotra & Kaufman, 2007; Moreno & Tiffany-Castiglioni, 2015; Soto, 2003; Zhao & Ackerman, 2006).”
BackgroundInfluentialFormella, I., Svahn, A. J., Radford, R. A. W., Don, E. K., Cole, N. J., Hogan, A. L., Lee, A., Chung, R. S., & Morsch, M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.08.011 · Cited by 55
Yu, A., Fox, S. G., Cavallini, A., Kerridge, C., O’Neill, M. J., Wolak, J., Bose, S., & Morimoto, R. I. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007527 · Cited by 54
“The cellular pathology of protein misfolding diseases is initiated by highly aggregation-prone proteins that can convert to oligomeric species with a propensity to form aggregates and amyloids (1-4).”
BackgroundWalker, A. C., Bhargava, R., Vaziriyan-Sani, A. S., Pourciau, C., Donahue, E. T., Dove, A. S., Gebhardt, M. J., Ellward, G. L., Romeo, T., & Czyż, D. M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009510 · Cited by 62
“Neurodegenerative protein conformational diseases (PCDs), including amyotrophic lateral sclerosis (ALS), Alzheimer’s, Huntington’s, and Parkinson’s disease, are characterized by the misfolding and aggregation of metastable proteins that reside within the proteome, often resulting in loss of tissue function that manife…”
BackgroundFunctional Role of the Disulfide Isomerase ERp57 in Axonal Regeneration
Castillo, V., Oñate, M., Woehlbier, U., Rozas, P., Andreu, C. I., Medinas, D. B., Valdés, P., Osorio, F., Mercado, G., Vidal, R. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136620 · Cited by 57
“Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), among other brain pathologies; and are now classified as protein misfolding disorders (PMDs) [1].”
Duim, W. C., Chen, B., Frydman, J., & Moerner, W. E. (2011) · ChemPhysChem · doi:10.1002/cphc.201100392 · Cited by 54
Disulfide Bonding in Neurodegenerative Misfolding Diseases
Mossuto, M. F. (2013) · International Journal of Cell Biology · doi:10.1155/2013/318319 · Cited by 57
“In each case a specific protein loses its functional structure to populate partially unfolded species that reorganize themselves into polymeric structures with different degrees of ordered structure, from oligomers to amyloid fibrils [1].”
BackgroundSocías, S. B., González‐Lizárraga, F., Ávila, C. L., Vera, C., Acuña, L., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Chehín, R. N. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.002 · Cited by 59
“…and Huntington’s diseases (HD), among others, are currently being classified under a similar molecular and cellular mechanism whereby protein aggregation appears to be involved in triggering and spreading neuronal death in specific brain regions (Soto, 2003; Soto et al., 2006; Takalo et al., 2013).”
BackgroundTetz, G. V., & Tetz, V. (2022) · Microorganisms · doi:10.3390/microorganisms10020280 · Cited by 54
Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology
Agarwal, M., Alam, R., Haider, M. K., Malik, M. Z., & Kim, D.-K. (2020) · Nanomaterials · doi:10.3390/nano11010059 · Cited by 63
Chien, V., Aitken, J. F., Zhang, S., Buchanan, C. M., Hickey, A. J., Brittain, T., Cooper, G. J. S., & Loomes, K. M. (2010) · Biochemical Journal · doi:10.1042/bj20100434 · Cited by 61
Makioka, K., Yamazaki, T., Fujita, Y., Takatama, M., Nakazato, Y., & Okamoto, K. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.06.019 · Cited by 58
“The regional distribution in the brain and the composition of protein aggregates are different in each neurodegenerative disease [5].”
BackgroundTavassoly, O., Kakish, J., Nokhrin, S. M., Dmitriev, O. Y., & Lee, J. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.090 · Cited by 56
Surface Effects Mediate Self-Assembly of Amyloid-β Peptides
Lin, Y., Petersson, E. J., & Fakhraai, Z. (2014) · ACS Nano · doi:10.1021/nn5031669 · Cited by 54
Action of Caffeine as an Amyloid Inhibitor in the Aggregation of Aβ16–22 Peptides
Sharma, B., & Paul, S. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b03892 · Cited by 56
Arora, H., Ramesh, M., Rajasekhar, K., & Govindaraju, T. (2020) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20190356 · Cited by 58
Cunningham, C., Wilcockson, D. C., Boche, D., & Perry, V. H. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5174-5184.2005 · Cited by 53
“The prion diseases (transmissible spongiform encephalopathies) share similarities with other neurodegenerative conditions, such as amyotrophic lateral sclerosis and Alzheimer’s, Parkinson’s, and Huntington’s diseases, in that they are characterized by the deposition of insoluble protein plaques, neurodegeneration alon…”
Onoda, A., Kawasaki, T., Tsukiyama∥, K., Takeda, K., & Umezawa, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-66744-w · Cited by 56
Liu, Y., Lee, S. Y., Neely, E., Nandar, W., Moyo, M., Simmons, Z., & Connor, J. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.170944 · Cited by 54
Shamoto‐Nagai, M., Hisaka, S., Naoi, M., & Maruyama, W. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-25 · Cited by 57
Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review
Pansieri, J., Gerstenmayer, M., Lux, F., Mériaux, S., Tillement, O., Forge, V., Larrat, B., & Marquette, C. (2018) · Nanomaterials · doi:10.3390/nano8090740 · Cited by 52
“A third group of diseases related to amyloid deposits concerns neurodegenerative diseases, such as amyloid β (Aβ) in Alzheimer’s disease (AD), α-synuclein (α-syn) in Parkinson’s disease (PD), or prion protein (PrP) in Creutzfeldt–Jakob disease, which are the most studied amyloidoses due to their major clinical impacts…”
BackgroundPharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer’s disease
Pradeepkiran, J. A., Reddy, A. P., & Reddy, P. H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.005 · Cited by 52
Sequeira, I. R., & Poppitt, S. D. (2017) · Nutrients · doi:10.3390/nu9070788 · Cited by 56
“Evidence linking protein misfolding and aggregation with disease comes from post-mortem histopathological studies, where a typical feature of each disease is the accumulation of protein deposits; namely, amyloid β (Aβ) in AD, α-synuclein in PD, and poly-Q expanded Huntington in HD [99].”
BackgroundInfluentialAn ALS ‐associated KIF5A mutant forms oligomers and aggregates and induces neuronal toxicity
Nakano, J., Chiba, K., & Niwa, S. (2022) · Genes to Cells · doi:10.1111/gtc.12936 · Cited by 54
“Aggregates change cellular metabolisms and induces neuronal death (Soto, 2003).”
BackgroundNeurodegenerative diseases: exercising towards neurogenesis and neuroregeneration
Ang, E. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00025 · Cited by 55
“Nonetheless, these factors are obviously the most prominent therapeutic targets (Mudher and Lovestone, 2002; Soto, 2003; Mattson, 2004; Roberson and Mucke, 2006; Bates et al., 2009).”
Hacking the Code of Amyloid Formation
Pastor, M. T., Esteras‐Chopo, A., & Serrano, L. G. (2007) · Prion · doi:10.4161/pri.1.1.4100 · Cited by 51
Zhao, T., Hong, Y., Yin, P., Li, S., & Li, X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710549114 · Cited by 54
“P misfolding causes a wide range of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and polyglutamine diseases, such as Huntington’s disease (HD) (1).”
BackgroundThermoresponsive BSA hydrogels with phase tunability
Khanna, S., Singh, A. K., Behera, S. P., & Gupta, S. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111590 · Cited by 52
Gersting, S. W., Lagler, F. B., Eichinger, A., Kemter, K. F., Danecka, M. K., Messing, D. D., Staudigl, M., Domdey, K. A., Zsifkovits, C., Fingerhut, R., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq085 · Cited by 52
Rousseau, E., Dehay, B., Ben-Haïem, L., Trottier, Y., Morange, M., & Bertolotti, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403015101 · Cited by 52
Meessen-Pinard, M., Coupanec, A. L., Desforges, M., & Talbot, P. J. (2016) · Journal of Virology · doi:10.1128/jvi.01513-16 · Cited by 51
Iavarone, A. T., Duft, D., & Parks, J. H. (2006) · The Journal of Physical Chemistry A · doi:10.1021/jp064933e · Cited by 58
Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells
Whiten, D. R., Zuo, Y., Calo, L., Choi, M., De, S., Flagmeier, P., Wirthensohn, D. C., Kundel, F., Ranasinghe, R. T., Sanchez, S. E., et al. (2018) · ChemBioChem · doi:10.1002/cbic.201800209 · Cited by 53
Fibrillar and Nonfibrillar Amyloid Beta Structures Drive Two Modes of Membrane-Mediated Toxicity
Zanden, C. M. V., Wampler, L., Bowers, I., Watkins, E. B., Majewski, J. P., & Chi, E. Y. (2019) · Langmuir · doi:10.1021/acs.langmuir.9b02484 · Cited by 52
Overview of Protein Aggregation in Single, Double, and Triple Neurodegenerative Brain Amyloidoses
Trojanowski, J. Q., & Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:1 · Cited by 61
“…embark on drug discovery efforts to develop more effective therapies for protein misfolding diseases, including neurodegenerative brain amyloidoses, such as AD, synucleinopathies, and tauopathies (Mayeux and Sano, 1999; Irizarry and Hyman, 2001; Trojanowski, 2002; Loo and Clarke, 2003; Soto, 2003).”
InfluentialSoluble oligomers for the diagnosis of neurodegenerative diseases
El‐Agnaf, O. M. A., Walsh, D. M., & Allsop, D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00481-2 · Cited by 50
Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes
Chegão, A., Guarda, M., Alexandre, B. M., Shvachiy, L., Temido‐Ferreira, M., Marques-Morgado, I., Gomes, B. F., Matthiesen, R., Lopes, L. V., Florindo, P. R., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00314-x · Cited by 52
Titration of biologically active amyloid–β seeds in a transgenic mouse model of Alzheimer's disease
Morales, R., Bravo-Alegria, J., Duran-Aniotz, C., & Soto, C. (2015) · Scientific Reports · doi:10.1038/srep09349 · Cited by 49
Self-citationReactive Species in Huntington Disease: Are They Really the Radicals You Want to Catch?
Bono-Yagüe, J., Gómez-Escribano, A. P., Millán, J. M., & Vázquez‐Manrique, R. P. (2020) · Antioxidants · doi:10.3390/antiox9070577 · Cited by 55
Emerging potential of cannabidiol in reversing proteinopathies
Dash, R., Ali, M. C., Jahan, I., Munni, Y. A., Mitra, S., Hannan, M. A., Timalsina, B., Oktaviani, D. F., Choi, H. J., & Moon, I. S. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101209 · Cited by 51
“These protein aggregates can interact with the lipid bilayer of the cell membranes, causing membrane disruption or pore formation (Andreasen et al., 2015; Di Scala et al., 2016), which eventually disrupts ion homeostasis (Shrivastava et al., 2017; Soto, 2003).”
BackgroundDiseases of protein aggregation and the hunt for potential pharmacological agents
Wang, S. S. ‐., Wu, J. W., Yamamoto, S., & Liu, H. (2008) · Biotechnology Journal · doi:10.1002/biot.200700065 · Cited by 49
“As the bounded molecules accumulate at these sites, the size of the protein assemblies gradually increases [24, 25].”
BackgroundProtein quality control: the who’s who, the where’s and therapeutic escapes
Roth, J., Yam, G. H., Fan, J., Hirano, K., Gaplovská-Kyselá, K., Fourn, V. L., Guhl, B., Santimaria, R., Torossi, T., Ziak, M., et al. (2007) · Histochemistry and Cell Biology · doi:10.1007/s00418-007-0366-7 · Cited by 53
“…have been observed in association with a number of chronic neurodegenerative diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis (Johnston et al. 2000; Kabashi and Durham 2006; Rubinsztein 2006; Selkoe 2003; Shults 2006; Soto 2003).”
BackgroundLutter, L., Serpell, C. J., Tuite, M. F., & Xue, W. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.07.010 · Cited by 53
“identified in many human pathologies [1], including amyloid β (Aβ) and tau involved in Alzheimer’s disease (AD), α-synuclein (α-syn) in Parkinson’s disease, and huntingtin in”
BackgroundGlycation modulates alpha-synuclein fibrillization kinetics: A sweet spot for inhibition
Farzadfard, A., König, A., Petersen, S. V., Nielsen, J., Vasili, E., Dominguez‐Meijide, A., Buell, A. K., Outeiro, T. F., & Otzen, D. E. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101848 · Cited by 50
“Nevertheless, PD is thought to be associated with the tendency of αSN to form oligomeric and amyloid-like aggregates (19).”
BackgroundSIRT1 Knockdown Promotes Neural Differentiation and Attenuates the Heat Shock Response
Liu, D. J., Hammer, D., Komlos, D., Chen, K. Y., Firestein, B. L., & Liu, A. Y. ‐. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24556 · Cited by 50
“…likely contribute to the attenuatedHSR and underlie the vulnerability of neurons to the dire consequence of protein misfolding and aggregation particularly in the aging cell and organism (Soto, 2003; Forman et al., 2004; Muchowski and Wacker, 2005; Lansbury and Lashuel, 2006; Morimoto, 2008).”
BackgroundTalaei, F., van Praag, V. M., Shishavan, M. H., Landheer, S. W., Buikema, H. J., & Henning, R. H. (2014) · BMC Cell Biology · doi:10.1186/1471-2121-15-1 · Cited by 51
“Protein aggregate formation affects cellular function and has been implicated in various aging related disorders [10] and complications [11].”
BackgroundProtein Misfolding during Pregnancy: New Approaches to Preeclampsia Diagnostics
Gerasimova, E. M., Fedotov, S. A., Kachkin, D. V., Vashukova, E. S., Glotov, A. S., Chernoff, Y. O., & Rubel, A. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246183 · Cited by 52
“Amyloids are highly organized non-covalent cross-β protein polymers that could accumulate in the form of fibrils of 7–10 nm in diameter and are highly resistant to anti-protein agents [76].”
BackgroundPathological Crosstalk Between Oxidized LDL and ER Stress in Human Diseases: A Comprehensive Review
Varghese, D. S., & Ali, B. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674103 · Cited by 50
“Alzheimer’s disease (AD), Amyotropic Lateral Sclerosis (ALS) and Parkinson’s disease are categorized under this class of diseases with a characteristic long clinically silent phase (Soto, 2003; Selkoe, 2004).”
BackgroundAggregate formation and synaptic abnormality induced by DSCR1
Ma, H., Xiong, H., Liu, T., Zhang, L., Godzik, A., & Zhang, Z. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02294.x · Cited by 48
“Aggregation of cellular proteins into insoluble complexes and inclusion bodies is linked to the pathogenesis of most human neurodegenerative diseases (Sherman and Goldberg 2001; Soto 2003).”
BackgroundBlat, D., Weiner, L., Youdim, M. B. H., & Fridkin, M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070800l · Cited by 48
Heidarsson, P. O., Naqvi, M. M., Otazo, M. R., Mossa, A., Kragelund, B. B., & Cecconi, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401065111 · Cited by 57
“Despite both Ca homeostasis and protein misfolding being linked to neurodegeneration (5, 59), a direct causation between the two former has been missing.”
BackgroundInfluentialThe intriguing prion disorders
Abid, K., & Soto, C. A. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6140-5 · Cited by 59
Self-citationTreatments for behavioural disorders in neurodegenerative diseases: drug development strategies
Cummings, J. L., & Zhong, K. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1928 · Cited by 49
“Key NDDs have been linked to abnormalities of protein metabolism and protein misfoldin”
BackgroundHigh Accuracy Protein Identification: Fusion of Solid‐State Nanopore Sensing and Machine Learning
Dutt, S., Shao, H., Karawdeniya, B. I., Bandara, Y. M. N. D. Y., Daskalaki, E., Suominen, H., & Kluth, P. (2023) · Small Methods · doi:10.1002/smtd.202300676 · Cited by 52
Seidel, K., Meister, M., Dugbartey, G. J., Zijlstra, M. P., Vinet, J., Brunt, E. R. P., van Leeuwen, F. W., Rüb, U., Kampinga, H. H., & den Dunnen, W. F. A. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01220.x · Cited by 50
First passage times in homogeneous nucleation and self-assembly
Yvinec, R., D'Orsogna, M. R., & Chou, T. (2012) · The Journal of Chemical Physics · doi:10.1063/1.4772598 · Cited by 47
Kalathur, R. K. R., Giner‐Lamia, J., Machado, S., Barata, T., Ayasolla, K., & Futschik, M. E. (2015) · F1000Research · doi:10.12688/f1000research.6358.2 · Cited by 48
“UPR and HD ER stress and UPR have been indicated for a variety of neurodegenerative disorders, where protein misfolding plays a significant role 17–19 .”
Prion degradation pathways: Potential for therapeutic intervention
Goold, R., McKinnon, C., & Tabrizi, S. J. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.12.009 · Cited by 56
“As a result, prion diseases are included in a group of neurodegenerative disorders termed the proteinopathies, alongside Alzheimer's disease (AD), Parkinson's disease (PD) andHuntington's disease (HD) (Soto, 2003).”
Nanduri, P., Hao, R., Fitzpatrick, T., & Yao, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.627950 · Cited by 48
“The appearance of inclusion bodies is a pathological hallmark of many neurodegenerative disorders (1, 2).”
BackgroundPhthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation
Valiente‐Gabioud, A. A., Miotto, M., Chesta, M. E., Lombardo, V. A., Binolfi, A., & Fernández, C. O. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00507 · Cited by 51
Pore-Forming Proteins as Mediators of Novel Epigenetic Mechanism of Epilepsy
Surguchov, A. P., Surgucheva, I. G., Sharma, M., Sharma, R. A., & Singh, V. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00003 · Cited by 48
Metal ions affect the formation and stability of amyloid β aggregates at multiple length scales
Lee, M., Kim, J. I., Na, S., & Eom, K. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp05072k · Cited by 47
Longo, F., Mancini, M., Ibraheem, P. L., Aryal, S., Mesini, C., Patel, J. C., Penhos, E., Rahman, N., Mamcarz, M., Santini, E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01099-w · Cited by 53
“activation results in synaptic failure, impaired synaptic plasticity, and ultimately, cell death [26, 27].”
BackgroundHERV-K Modulates the Immune Response in ALS Patients
Arru, G., Galleri, G., Deiana, G. A., Zarbo, I. R., Sechi, E., Bo, M., Cadoni, M. P. L., Corda, D. G., Frau, C., Simula, E. R., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9081784 · Cited by 48
“ALS is characterized by heterogeneous clinical signs and symptoms, and a definite diagnosis may require 13 to 18 months, once of other disorders that can affect upper and lower motor neurons have been excluded [11,12].”
BackgroundAmyloid Inhibitors and β-Sheet Breakers
Soto, C. A., & Estrada, L. D. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_18 · Cited by 52
Self-citationTabner, B. J., Turnbull, S., Fullwood, N. J., German, M., & Allsop, D. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330548 · Cited by 47
Vasireddy, V., Jablonski, M. M., Khan, N. W., Wang, X. F., Sahu, P., Sparrow, J. R., & Ayyagari, R. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2009.07.021 · Cited by 48
“Abnormal protein accumulation has been reported in different forms of macular degenerations, retinal degenerations and other neurodegenerations (Rajan et al., 2001; Saliba et al., 2002; Soto, 2003; Klenotic et al., 2004; Soto and Estrada, 2008).”
Single particle detection and characterization of synuclein co-aggregation
Giese, A., Bader, B., Bieschke, J., Schaffar, G., Odoy, S., Kahle, P. J., Haass, C., & Kretzschmar, H. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.025 · Cited by 58
β-Amyloid-derived pentapeptide RIIGLa inhibits Aβ1–42 aggregation and toxicity
Fülöp, L., Zarándi, M., Datki, Z., Soós, K., & Penke, B. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.024 · Cited by 53
Combating neurodegenerative disease with chemical probes and model systems
Narayan, P. S., Ehsani, S., & Lindquist, S. L. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1663 · Cited by 60
Gamarra, L. F., Sibov, T. T., Pavon, L. F., Miyaki, L. A. M., Mamani, J. B., Nucci, L. P., Alvarim, L. T., Silveira, P., & Marti, L. C. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s53299 · Cited by 48
“These diseases affect the gray matter of the central nervous system, mainly by progressive loss of neurons with associated secondary changes in the white matter tracts, causing irreversible destruction of nervous tissue.(7,8) In vivo studies have demonstrated a stem cell treatment approach to enhance neuroprotective m…”
van Marle, G., & Power, C. (2005) · Journal of NeuroVirology · doi:10.1080/13550280590922838 · Cited by 48
“…an altered expression pattern of the envelope protein within the endoplasmic reticulum as a consequence of individual mutations, leading to a stress response that results in the release of neurotoxins , as suggested for studies of misfolded proteins in other neurodegenerative diseases (Soto, 2003).”
BackgroundA central role for calcineurin in protein misfolding neurodegenerative diseases
Shah, S. Z. A., Hussain, T. A., Zhao, D., & Yang, L. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2379-7 · Cited by 47
Exploring the power of yeast to model aging and age-related neurodegenerative disorders
Oliveira, A. V., Vilaça, R., dos Santos, C. N., Costa, V., & Menezes, R. (2016) · Biogerontology · doi:10.1007/s10522-016-9666-4 · Cited by 58
“These diseases can arise from hereditary and sporadic conditions and have a complex pathogenesis triggering atrophy of central or peripheral structures of the nervous system (Soto 2003).”
BackgroundGarcía-González, P. A., Cabral‐Miranda, F., Hetz, C. A., & Osorio, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02541 · Cited by 50
“Conversely, therapeutic gene delivery of active UPR components or ER chaperones to specific brain areas has shown outstanding effects in different animal models of PMDs (43).”
BackgroundInfluentialObservation of molecular inhibition and binding structures of amyloid peptides
Wang, C., Yang, A., Li, X., Li, D., Zhang, M., Du, H., Li, C., Guo, Y., Mao, X., Dong, M., et al. (2012) · Nanoscale · doi:10.1039/c2nr11508e · Cited by 46
Chaperone-Mediated Autophagy and Its Implications for Neurodegeneration and Cancer
Assaye, M. A., & Gizaw, S. T. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s368364 · Cited by 45
Aged rats are hypo-responsive to acute restraint: implications for psychosocial stress in aging
Buechel, H. M., Popović, J., Staggs, K. E., Anderson, K. L., Thibault, O., & Blalock, E. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00013 · Cited by 54
“…including free radical damage (Finkel and Holbrook, 2000; Cutler et al., 2004; Poon et al., 2004), protein misfolding (Wickner et al., 1999; Soto, 2003), calcium ion dyshomeostasis (Landfield, 1987; Khachaturian, 1989; Landfield et al., 1992; Foster et al., 2001; Toescu and Verkhratsky,…”
BackgroundTargeting of the unfolded protein response (UPR) as therapy for Parkinson's disease
Martinez, A. N., López, N., González, C., & Hetz, C. A. (2019) · Biology of the Cell · doi:10.1111/boc.201800068 · Cited by 49
“These diseases are collectively referred as proteinopathies or protein misfolded disorders (PMDs) [Soto, 2003; Bertram and Tanzi, 2005; Aguzzi and O’Connor, 2010].”
BackgroundPrion-Like Protein Aggregates and Type 2 Diabetes
Mukherjee, A., & Soto, C. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024315 · Cited by 51
“…Huntington’s disease (HD), the transmissible spongiform encepha- lopathies (TSEs), and amyotrophic lateral sclerosis (ALS), as well as diverse systemic disorders such as familial amyloid polyneuropathy, type 2 diabetes (T2D), secondary amyloidosis, and dialysis-related amyloidosis (Soto 2003).”
BackgroundInfluentialSelf-citationMollereau, B., Rzechorzek, N. M., Roussel, B. D., Sedru, M., van den Brink, D. M., Bailly‐Maitre, B., Palladino, F., Medinas, D. B., Domingos, P. M., Hunot, S., et al. (2016) · Brain Research · doi:10.1016/j.brainres.2016.02.033 · Cited by 49
“PMD was supported by Fundação para a Ciência e a Tecnologia (FCT-ANR/NEU-NMC/0006/2013).”
BackgroundInfluentialBlocquel, D., Li, S., Wei, N., Daub, H., Sajish, M., Erfurth, M., Kooi, G., Zhou, J., Bai, G., SCHIMMEL, P. R., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx455 · Cited by 48
Macro roles for microRNAs in neurodegenerative diseases
Rajgor, D. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.07.001 · Cited by 49
Studencka‐Turski, M., Çetin, G., Junker, H., Ebstein, F., & Krüger, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02900 · Cited by 46
“Alterations in the proteostasis network upon UPS impairment, in particular disturbances to the function of endoplasmic reticulum (ER), are known to contribute to uncontrolled protein aggregation (14, 15).”
BackgroundPathophysiological Role of Organelle Stress/Crosstalk in AKI-to-CKD Transition
Maekawa, H., & Inagi, R. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.10.007 · Cited by 47
Châari, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.170 · Cited by 45
Co-Chaperones in Targeting and Delivery of Misfolded Proteins to the 26S Proteasome
Abildgaard, A. B., Gersing, S. K., Larsen-Ledet, S., Nielsen, S. V., Stein, A., Lindorff‐Larsen, K., & Hartmann‐Petersen, R. (2020) · Biomolecules · doi:10.3390/biom10081141 · Cited by 45
Zhu, L., Li, R., Jiao, S., Wei, J., Yan, Y., Wang, Z. A., Li, J., & Du, Y. (2020) · Marine Drugs · doi:10.3390/md18100488 · Cited by 48
“It is proven that Aβ aggregates containing cross-β-sheet structures lead to oxidative stress, neuroinflammation, and neuronal loss via multiple pathways [3,28].”
BackgroundBomhoff, G., Sloan, K., McLain, C., Gogol, E. P., & Fisher, M. T. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.02.001 · Cited by 46
Design of model systems for amyloid formation: lessons for prediction and inhibition
Pastor, M. T., Esteras‐Chopo, A., & de la Paz, M. L. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.01.004 · Cited by 49
“com themes to investigate include how self-association of a misfolded protein results in organ dysfunction and neurodegeneration, what are the toxic species, and whether or not aggregates of all proteins are toxic [2].”
BackgroundMisfolding of short-chain acyl-CoA dehydrogenase leads to mitochondrial fission and oxidative stress
Schmidt, S. P., Corydon, T. J., Pedersen, C. B., Bross, P., & Gregersen, N. V. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.03.009 · Cited by 45
“In neurodegenerative diseases associated with abnormal protein conformations such as Alzheimer’ disease, Parkinson’ disease, and Amyotrophic Lateral Sclerosis, evidence of a similar pathogenesis of these diseases has been reported [11,35,36], regardless of differences in the composition of misfolded protein–aggregates…”
Ubiquitin Stability and the Lys 63‐Linked Polyubiquitination Site Are Compromised on Copper Binding
Milardi, D., Arnesano, F., Grasso, G., Magrì, A. L., Tabbı̀, G., Scintilla, S., Natile, G., & Rizzarelli, E. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701987 · Cited by 44
Use of cell-permeable peptides to prevent neuronal degeneration
Borsello, T., & Bonny, C. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.03.008 · Cited by 44
Role of Polyphosphate in Amyloidogenic Processes
Lempart, J., & Jakob, U. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034041 · Cited by 46
“2) (Soto 2003).”
Zhuang, W., Sgourakis, N. G., Li, Z., Garcı́a, A. E., & Mukamel, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002131107 · Cited by 43
“Understanding this process is essential for designing therapeutics that target amyloid formation at an early stage of the disease (5).”
BackgroundStrain-dependent profile of misfolded prion protein aggregates
Morales, R., Hu, P. P., Duran-Aniotz, C. A., Moda, F., Díaz‐Espinoza, R., Chen, B., Bravo-Alegria, J. B., Makarava, N., Baskakov, I. V., & Soto, C. A. (2016) · Scientific Reports · doi:10.1038/srep20526 · Cited by 45
Self-citationChiroma, S. M., Baharuldin, M. T. H., Taib, C. N. M., Amom, Z., Jagadeesan, S., Adenan, M. I., Mahdi, O., & Moklas, M. A. M. (2019) · Toxics · doi:10.3390/toxics7020019 · Cited by 48
Amyloid-Like Aggregation in Diseases and Biomaterials: Osmosis of Structural Information
Balasco, N., Diaferia, C., Morelli, G., Vitagliano, L., & Accardo, A. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.641372 · Cited by 45
“The characterization of this proteinaceous material has unraveled a supramolecular organization in which synergic non-covalent interactions generally lead to the formation of extremely stable and low soluble structures (Soto, 2003; Chiti and Dobson, 2017).”
BackgroundGeneration of Hydrogen Peroxide from Mutant Forms of the Prion Protein Fragment PrP121−231
Turnbull, S., Tabner, B. J., Brown, D. R., & Allsop, D. (2003) · Biochemistry · doi:10.1021/bi030036e · Cited by 43
Endoplasmic Reticulum Stress Impairs Insulin Signaling through Mitochondrial Damage in SH-SY5Y Cells
Koo, H.-J., Piao, Y., & Pak, Y. K. (2012) · Neurosignals · doi:10.1159/000333069 · Cited by 46
Metadata
- Authors
- Soto, C.
- Corresponding author
- Soto, Claudio
- ORCID
- Soto, Claudio
- Venue
- Nature Reviews Neuroscience
- Published
- 2003-01
- Volume
- 4
- Issue
- 1
- Pages
- 49-60
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2007157911
- Cited by
- 1,506
- References
- 154
- Citations by year
- 2026: 45 · 2025: 70 · 2024: 75 · 2023: 73 · 2022: 95 · 2021: 88 · 2020: 107 · 2019: 80 · 2018: 86 · 2017: 107 · 2016: 92 · 2015: 75 · 2014: 67 · 2013: 45 · 2012: 57
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- protein misfolding, neurodegenerative diseases, protein aggregation, protein accumulation, neuronal apoptosis, common pathogenic mechanisms, therapeutic target
- MeSH terms
- Animals, Brain, Brain Chemistry, Humans, Protein Folding, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.